Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01539915 | Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients | PHASE1 | COMPLETED | 12 | — | — | Apr 1, 2007 | - | Feb 28, 2012 | 1 | Austria |
| NCT00417820 | Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis. | PHASE1 | COMPLETED | 35 | — | — | Nov 1, 2006 | Nov 1, 2007 | Nov 29, 2007 | 1 | Austria |
Interstitial fluid will be collected and concentrations of BCT194 determined determined on Day 1 and Day 8 at several timepoints
Interstitial fluid will be collected and concentrations of BCT194 determined on Day 1 and Day 8 at several timepoints
| Arm | Type | Description |
|---|---|---|
| BCT194 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BCT194 | DRUG | Topically applied BCT194 cream (0.5%) |
Inclusion criteria: * Male patients and post menopausal or surgically sterile female patients aged 18 - 75 years. * Diagnosis of stable plaque psoriasis (with or without arthritis); diagnosed or history of psoriasis for at least 6 months prior to screening * Psoriatic plaques accessible for micrope...